--- title: "BioMarin Pharmaceutical Earnings: What To Look For From BMRN" description: "Biotech company BioMarin Pharmaceutical is set to report earnings on Monday after market close. Last quarter, it met revenue expectations with $776.1 million, a 4.1% year-on-year increase, but missed " type: "news" locale: "en" url: "https://longbridge.com/en/news/276525143.md" published_at: "2026-02-22T03:07:03.000Z" --- # BioMarin Pharmaceutical Earnings: What To Look For From BMRN > Biotech company BioMarin Pharmaceutical is set to report earnings on Monday after market close. Last quarter, it met revenue expectations with $776.1 million, a 4.1% year-on-year increase, but missed EPS guidance. This quarter, revenue is expected to grow 11.6%, down from 15.6% last year. Analysts have maintained their estimates, despite BioMarin's history of missing revenue targets. In comparison, peers Biogen and Halozyme Therapeutics reported varied results. BioMarin's stock has risen 13.9% recently, with an average analyst price target of $88.87 against a current price of $64.08. Biotech company BioMarin Pharmaceutical will be reporting results this Monday after market close. Here’s what to look for. BioMarin Pharmaceutical met analysts’ revenue expectations last quarter, reporting revenues of $776.1 million, up 4.1% year on year. It was a softer quarter for the company, with a significant miss of analysts’ full-year EPS guidance estimates and a significant miss of analysts’ EPS estimates. Is BioMarin Pharmaceutical a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members. This quarter, the market is expecting BioMarin Pharmaceutical’s revenue to grow 11.6% year on year, slowing from the 15.6% increase it recorded in the same quarter last year. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. BioMarin Pharmaceutical has missed Wall Street’s revenue estimates multiple times over the last two years. Looking at BioMarin Pharmaceutical’s peers in the therapeutics segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Biogen delivered year-on-year revenue growth of 1.2%, beating analysts’ expectations by 3.6%, and Halozyme Therapeutics reported revenues up 51.6%, topping estimates by 0.6%. Biogen traded up 4.6% following the results while Halozyme Therapeutics was down 9%. Read our full analysis of Biogen’s results here and Halozyme Therapeutics’s results here. The euphoria surrounding Trump’s November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the therapeutics stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.2% on average over the last month. BioMarin Pharmaceutical is up 13.9% during the same time and is heading into earnings with an average analyst price target of $88.87 (compared to the current share price of $64.08). ### Related Stocks - [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md) - [BIIB.US - Biogen](https://longbridge.com/en/quote/BIIB.US.md) - [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md) - [HALO.US - Halozyme Therap](https://longbridge.com/en/quote/HALO.US.md) - [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md) - [BMRN.US - BioMarin Pharma](https://longbridge.com/en/quote/BMRN.US.md) - [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md) - [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md) - [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md) - [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 拜玛林制药未来收益展望 | 生物制药公司（Biomarin Pharmaceutical，NASDAQ:BMRN）将于 2026 年 2 月 23 日公布季度财报，分析师预计每股收益（EPS）为 0.41 美元。投资者希望能有积极的指引公告。上个季度，该公司每股收益未 | [Link](https://longbridge.com/en/news/276450980.md) | | 分析师的判决：18 位专家眼中的安进 | 安进（NASDAQ:AMGN）在过去三个月内获得了 18 位分析师的混合评级，平均 12 个月目标价为 350.61 美元，比之前的目标上涨了 6.93%。分析师们提高了他们的评级和目标价，其中富国银行和派珀·桑德勒等公司的增幅尤为显著。安 | [Link](https://longbridge.com/en/news/276494592.md) | | 深入解析 Insmed：16 位分析师分享他们的看法 | 在最新的季度中，16 位分析师对 Insmed（NASDAQ:INSM）给出了混合评级，平均 12 个月的目标价格为 224.19 美元，比之前的目标上涨了 0.99%。分析师们经常根据市场情况更新他们的建议，评级和目标价格也会发生显著变化 | [Link](https://longbridge.com/en/news/276472105.md) | | 查尔斯河实验室第四季度的收入略高于预期 | 查尔斯河第四季度的收入略微超过分析师预期，达到 9.942 亿美元，调整后的每股收益为 2.39 美元。公司预计有机收入增长将在 2026 年下半年恢复，预计 2026 年的收入将持平或增长 1.5%。面临的挑战包括 RMS 收入下降和 D | [Link](https://longbridge.com/en/news/276225954.md) | | Siligmueller & Norvid Wealth Advisors LLC 购入了 12,436 股艾伯维公司（AbbVie Inc.）的股票 | Siligmueller & Norvid Wealth Advisors LLC 在第三季度收购了 12,436 股艾伯维（AbbVie Inc.，纽约证券交易所代码：ABBV），价值约 288 万美元，使其成为该公司的第 25 大持股。 | [Link](https://longbridge.com/en/news/276513386.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.